This site is intended for healthcare professionals only

COVID-19: New measures to support safe vaccines announced

Written by: | Published:

A vaccine for coronavirus is in development A vaccine for coronavirus is in development

A range of plans to ensure the safe future mass rollout of a COVID-19 vaccine have been announced by the government.

The measures include reinforced safeguards to support the Medicines and Healthcare products Regulatory Agency to grant temporary authorisation for the use of a new COVID-19 vaccine; expanding the trained workforce who can administer COVID-19 and flu vaccines to improve access and protect the public; and clarifying the scope of the protection from civil liability for the additional workforce that could be allowed to administer vaccinations.

‘We are making progress in developing COVID-19 vaccines which we hope will be important in saving lives, protecting healthcare workers and returning to normal in future,’ said Deputy Chief Medical Officer, Professor Jonathan Van-Tam.

‘If we develop effective vaccines, it’s important we make them available to patients as quickly as possible but only once strict safety standards have been met. The proposals consulted on today suggest ways to improve access and ensure as many people are protected from COVID-19 and flu as possible without sacrificing the absolute need to ensure that any vaccine used is both safe and effective.’

If a vaccine is discovered before 2021, the proposals will bolster existing powers that allow the MHRA to consider approving its use, before a full product licence is granted, provided it is proven to be safe and effective during robust and extensive clinical trials.

The regulations will permit the MHRA to consider giving temporary authorisation allowing patients to benefit while it undergoes the full licensing process, with reinforced conditions attached to ensure safety, quality and efficacy. This is a precautionary measure and will be used as a last resort if there is a strong public health justification for widespread use of a vaccine before it has been granted a product licence.

‘Protecting health and saving lives is at the heart of all our work. Throughout the pandemic, the MHRA has prioritised work to ensure rapid approval of robust clinical trials to test a range of medicines and vaccines, whilst maintaining the highest quality and safety standards,’ said Dr Christian Schneider, Director of National Institute for Biological Standards and Control, part of the MHRA.

‘Whilst the existing licensing system, or a new UK one from next year, is the preferred and expected route to supply any vaccine, these new measures will strengthen the regulatory regime and our ability to protect public health.’

What do you think? Leave a comment below or tweet your views to @IndyNurseMag

This material is protected by MA Healthcare Ltd copyright.
See Terms and Conditions.

Comments

Name
 
Email
 
Comments
 

Please view our Terms and Conditions before leaving a comment.

Change the CAPTCHA codeSpeak the CAPTCHA code
 

Most read articles from Practice Nursing Journal

Practice Nursing Journal latest issue and most read articles.

Click here to read a selection of free to access articles from Practice Nursing Journal

Newsletter

Sign up to the newsletter

About

Independent Nurse is the professional resource for primary care and community nurses, providing clinical articles for practice nurses and prescribers.

Newsletter

Subscribe to our newsletter and stay up to date with the latest nursing news.

Stay Connected

Stay social with Independent Nurse by following us on Twitter, liking us on Facebook or connecting on LinkedIn.

Archive

Need access to some of our older articles? You can view our archive, or alternatively contact us.

Contact Us

MA Healthcare Ltd.
St Jude's Church, Dulwich Road
London, SE24 0PB

Tel: +44 (0)20 7738 5454
Registered in England and Wales No. 01878373

Meet the team

Authors

Find out how to contribute to Independent Nurse here.